Immuneering (IMRX) EBIT (2020 - 2023)
Historic EBIT for Immuneering (IMRX) over the last 4 years, with Q4 2023 value amounting to -$16.3 million.
- Immuneering's EBIT fell 1656.76% to -$16.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$58.4 million, marking a year-over-year decrease of 1288.63%. This contributed to the annual value of -$58.4 million for FY2023, which is 1288.63% down from last year.
- As of Q4 2023, Immuneering's EBIT stood at -$16.3 million, which was down 1656.76% from -$13.9 million recorded in Q3 2023.
- Immuneering's 5-year EBIT high stood at -$3.6 million for Q2 2020, and its period low was -$16.3 million during Q4 2023.
- In the last 4 years, Immuneering's EBIT had a median value of -$11.6 million in 2022 and averaged -$10.5 million.
- In the last 5 years, Immuneering's EBIT crashed by 12156.21% in 2021 and then tumbled by 559.74% in 2023.
- Over the past 4 years, Immuneering's EBIT (Quarter) stood at -$5.8 million in 2020, then crashed by 90.45% to -$11.1 million in 2021, then dropped by 25.81% to -$14.0 million in 2022, then fell by 16.57% to -$16.3 million in 2023.
- Its EBIT stands at -$16.3 million for Q4 2023, versus -$13.9 million for Q3 2023 and -$13.5 million for Q2 2023.